NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / World News / Oxford/AstraZeneca first jab cuts COVID-19 transmission substantially: UK study
    Next Article
    Oxford/AstraZeneca first jab cuts COVID-19 transmission substantially: UK study

    Oxford/AstraZeneca first jab cuts COVID-19 transmission substantially: UK study

    By Nikita Gupta
    (PTI desk)
    Feb 03, 2021
    06:01 pm

    What's the story

    According to a new Oxford University study, the first dose of the two-dose Oxford/AstraZeneca vaccine can cut coronavirus transmissions by around 67 percent and therefore, have a substantial effect on controlling the spread.

    The UK Government described this as good news for the world because the impact of COVID-19 vaccines on transmission has been a crucial unknown in the fight against the pandemic.

    Research and results

    Three-month gap between two doses is effective

    The Oxford vaccine trial results, currently under review to be published by The Lancet, also found that the three-month interval between the two required doses proved effective.

    A single standard dose of the Oxford vaccine showed 76 percent efficacy from day 22 to day 90 after the jab, which means protection is not reduced in the three months between the first and second dose.

    Quote

    The Oxford vaccine is absolutely superb and works well: Hancock

    "This vaccine has shown a two-thirds reduction in transmission, stronger protection from the 12-week gap between doses, and no hospitalizations. It also reduces the number of people who have COVID-19 at all, even asymptomatically," said UK Health Secretary Matt Hancock.

    Further details

    New data verifies interim data used to grant EUA

    The new data provides important verification of the interim data that was used by more than 25 regulators, including the MHRA and EMA, to grant emergency use authorization.

    "It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, and find optimal approach to roll out," said Professor Andrew Pollard, Chief Investigator, Oxford vaccine trial.

    COVID-19 response

    Interval of 12 weeks between doses raises efficacy to 82.4%

    The analysis found no cases of hospitalizations and that the effect of dosing interval on efficacy is pronounced, with vaccine efficacy rising from 54.9 percent with an interval of fewer than six weeks to 82.4 percent when spaced 12 or more weeks apart.

    This supports the UK government's strategy of the mass roll-out of the first doses, with a second dose after three months.

    Information

    9.6 million people in UK have been given first dose

    The findings are in line with previous research into vaccines of influenza, ebola, and malaria. The scientists are hoping to report data regarding vaccine's impact on new COVID-19 variants. The news comes when the National Health Service has covered 9.6 million people with first jabs.

    Different studies

    Antibodies against COVID-19 last up to six months: Related study

    A related study revealed that protective antibodies against COVID-19 last up to six months in most infected people. 88 percent of people showed these results, based on the UK Biobank data of almost 1,700 people.

    "We aren't certain how the presence of antibodies relates to immunity, but there's no subsequent infection for at least six months," said UK Biobank Chief Scientist Professor Naomi Allen.

    COVID-19 symptoms

    UK Biobank study gives more details about the symptoms

    The UK Biobank study, one of the world's largest follow-up COVID-19 studies, also provides more detail about the symptoms experienced by the infected.

    While 26 percent had a cough and 28 percent fever, 43 percent said they lost the sense of taste or smell. However, 40 percent reported none of these symptoms, and about 20 percent reported no symptoms of any kind at all.

    Information

    Blacks or South Asians more likely to have antibodies

    Additionally, the data found that among a group of nearly 20,000 people who were regularly tested monthly during the pandemic, it was younger adults, black or South Asian people, and those living in deprived areas who were most likely to test positive for the antibodies.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Coronavirus
    Serum Institute of India
    AstraZeneca

    Latest

    'Bhool Chuk Maaf,' 'Kapkapiii': Movies hitting theaters this Friday Amit Sadh
    Italian villa, Hyderabad mansion: Inside Prabhas's luxurious ₹124cr real-estate empire Baahubali
    You can now 'try on' clothes in Google search Google
    Google rolls out an AI tool for creating videos Google

    Coronavirus

    India calls for inclusive system for early vaccination of peacekeepers India
    COVID-19 pandemic may take four to five years to end Singapore
    United Kingdom crosses grim COVID-19 death toll of 100,000 Boris Johnson
    US to purchase additional 200 million coronavirus vaccine doses Pfizer

    Serum Institute of India

    Applying for Covishield's emergency approval in 2 weeks: SII Narendra Modi
    SII to sue vaccine trial participant for Rs. 100 crore Oxford
    SII says Covishield 'safe' after trial participant sends legal notice Oxford University
    Trial will continue: Centre on SII vaccine's "adverse reaction" claims Central Drugs Standard Control Organization (CDSCO)

    AstraZeneca

    COVID-19 vaccine: What are the latest updates? Oxford
    #GoodNews: Oxford's COVID-19 vaccine may be available by September-end Oxford
    As coronavirus pandemic surges, some vaccine makers expect to profit Pfizer
    Meet Adar Poonawalla, the man bringing COVID-19 vaccines to India Oxford University
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025